• Development of translational research studies (both animal and clinical studies) in cerebrovascular diseases, with the objectives of increasing the understanding of the pathogenesis of both cerebral infarction (with cortical and subcortical affectation) and cerebral hemorrhage. To identify prognostic biomarkers and therapeutic targets mainly aimed at the promotion of brain protection and repair, with a special interest on the development of cell therapy as well as in trophic factors, extracellular vesicles and remyelinizating drugs. Clinical trials of cell therapy in acute cerebral infarction (clinical trial AMASCIS and European Consortium RESSTORE-H2020).

• Development of innovative strategies in the diagnosis and treatment of ischemic stroke, through the development of an independent operator-ultrasound device for brain visualization and for enhancement by ultrasound of drug therapies (BDNF, exosomes) in the ischemic area.

• Evaluation of the benefit of the implementation of prehospital clinical scales able to identify of patients of cerebral artery occlusion susceptible to mechanical thrombectomy in order to shorten treatment delay and improve the prognosis of patients. Comparative analysis of benefit and risk of primary mechanical thrombectomy versus intravenous throm-bolysis in patients with acute ischemic stroke within the first 4.5 hours from onset.

• Study of the clinical (neurological and neuropsy-chological) and anthropological factors influencing functional recovery and reintegration of stroke pa tients as well as the compliance with the recommendations for secondary stroke prevention.

• Analysis of the expression of the phenomenon central painful awareness in different primary and secondary headaches.

Amyotrophic Lateral Sclerosis

• ECAS scale (Edinburgh Cognitive Assessment Scale) validation and adaptation to Spanish language. Analysis of the different profiles of cognitive impairment in ALS patients by means of the ECAS scale (Edimburgh Cognitive Assesment Scale).

• SOPHIA Project: European Project on harmonization and optimization of the production and procesing of samples for the study of biomarkers in ALS and other motor neuron diseases.

• Functional study of Autonomic Nervous System in Amyotrophic Lateral Sclerosis. Identification of differential patterns of the disease presentation and their impact on clinical outcome . Alzheimer´s disease.

• Study of the lysosomal pathway involvement in a model of neurodegeneration and cholesterol dysregulation in Alzheimer’s disease. Parkinson´s disease.

 • Tremor as a negative predictive factor in developing dementia associated with Parkinson’s disease.

 • Evaluation of the benefits and risks of continuous infusion of intraduodenal levodopa in idiopathic Parkinson’s disease. Hereditary ataxias.

• Assessment of therapeutic response to Frenkel training exercises enhanced by Wii game console in patients with cerebellar ataxia.

• Participation in the Registry of the European Consortium EFACTS (European Friedreich’s Ataxia Consortium for Translational Studies) aimed at improve the knowledge of the epigenetic mechanisms related to silencing the expression of frataxin and the pathogenesis of the disease, identification of biomarkers and genes modifying the clinical expression of the disease, development of new therapies as well as cellular and animal models for the study of Friedrich’s Ataxia. 

• Analysis of the medium and long term results of workshops on post-stroke care attended by family and patients during the hospitalization time for an acute stroke on the degree of knowledge and ack - nowledge of stroke and its risk factors.

• Evaluation of the perceived quality of physicianpatient-family communication in cerebrovascular diseases and dementias.

Multiple sclerosis

• Study of remyelinizators substances as a biomarker white matter lesion in multiple sclerosis patients.

• Analysis of white matter biomarkers in Theiler’s Mourine Encephalomyelitis Virus (TMEV) animal model. Development of new reparative therapies based on the enhancement of remyelinization in experimental animal model.

• Analysis of molecular and neuroimaging biomarkers of brain damage and repair in Multiple Sclerosis. 

• Evaluation of the Autonomic Nervous System in movement disorders.

• Evaluation of the Autonomic Nervous System in focal autonomic neuropathies and in Fabry disease.

• COMPASS-31 Study (collaboration with the Mayo Clinic): Registry of patients and controls with central and peripheral dysautonomia.

• Observational study of the clinical course of patients with Charcot-Marie-Tooth disease. Identification of prognostic factors.

• Efficacy of evaluation of Eslicarbazepine acetate in neuropathic pain in patients with peripheral neuropathies.

• Development and evaluation of intervention protocols in childhood insomnia treatment.

• Analysis of sleep microstructure in newborns with Prader Willi Syndrome.

• Study on the efficacy of child insomnia treatment with oral iron supplements against placeb.

• Evaluation of the benefit of the implementation of an outpatient clinic for first seizures.

• Analysis of factors influencing the recurrence of seizures, tolerance and adherences to drugs, during the first monotherapy in patients with epilepsia.

• Analysis of neuropsychological disorders in the primary generalized epilepsy.

• Evaluation of cognitive impact of antiepileptic treatment after the first seizure and at the start of the first monotherapy as well as in elderly patients with focal epilepsy.

• Influence of stress as a trigger of seizures in epilepsy.

• Depression and anxiety: impact on the therapeutic compliance of patients with epilepsy.

• Registry of patients treated with i.v. antiepileptic drugs. Analysis of indications, response and adverse events.

• Study and functional classification of the gait of pediatric patients with cerebral palsy.

• Study and functional classification of the gait of patients with familial spastic paraparesis.

• Gait analysis as a tool for the differential diagnosis bet - ween child cerebral palsy and PEF in paediatric patients.

• Cerebrovascular diseases.

• Neurodegenerative diseases.

• Neuroimmunology. Multiple sclerosis.

• Neuromuscular diseases and spinocerebellar ataxias. Motor neuron diseases Amyotrophic lateral sclerosis.

• Headache and neuropathic pain.

• Developmental disorders and neurological maturation (TRADESMA).